Trend Of Drug Use In Gastric Cancer And Apatinib For Centralized Monitoring Of Adverse Reactions Of Gastric Cancer In A Three Grade Hospital

Gastric cancer is very common in China of malignant neoplasms,both of the morbidity and mortality is high,which is a serious threat to human health.We have surgical treatment of early cancer and have a good prognosis.Howerer,most of gastric cancer have no clinical symptoms,which once discovered,have no chance to do operation.It is to late development,maybe spread to other organs,which is only treated by systemic chemotherapy,so that life is extended.Dispite of this method has strong adverse reactions,the patients have no choice,they always suffer great psychological pressure and physical pain.Apatinib is a small molecule anti-angiogenesis inhibitor,which is self-developed approved for the 1.1 new drug market by the State Administration of Food and Drug Administration,For the patients of advanced gastric adenocarcinoma or stomach-esophageal junction adenocarcinoma,which is the third lines treatment.It has widely used in clinic.The majority of patients have the ADR,such as hypertension,proteinuria,diarrhea,abdominal pain,bleeding and so on.These ADR caused the treatment is discontinued and patients’ conditions deteriorates.1.To investigate the treatment situation of patients with gastric cancer in a hospital,and analyze the trend of the incidence of gastric cancer and the trend of chemotherapy treatment in recent years.Consulted the case information of primary gastric cancer from 2013 to 2016 by using PASS rational drug use monitoring system and electronic medical record system,statistics analysis of usage and application of anticancer chemotherapy in patients with gastric cancer,and the basic situation of drug.By consulting the case,in 2216 cases of gastric cancer patients were included,of which 1 were male than female patients were about,the elderly(over 60 years)as the main body of gastric cancer in the population,but there is a trend of young.The combination of two drugs and the combination of three drugs are the main treatment methods.The basic drug 5-fluorouracil derivatives,platinum and paclitaxel still for anticancer therapy,and the application of oral preparation occupy a larger proportion of targeted therapy and application performance to highlight the vitality,the treatment of gastric cancer showing accurate individual therapy.2.The study was searched by Wanfang data,CNKI,CBM for case reports of ADR,and the key words contained Apatinib and ADR.Analyzed the case reports that met the eligibility criteria.A total of 122 reports of adverse reactions were collected.633 cases were reported.Through literature search,collect qualified mesylate apatinib adverse reaction of 122 references,case reports of 633 cases.Mesylate apatinib manual approved for adenocarcinoma of three line therapy combined with advanced gastric adenocarcinoma or stomach esophagus.There were 384 males and 249 females,and the number of males was about 1.5 times that of females.The maximum age of the patients was 78 years old,the youngest was 23 years old,with an average age of 56.7 ± 5.4 years old.The main clinical manifestations of adverse reactions were hypertension,hand foot syndrome,hemorrhage,proteinuria,and other symptoms.Among them,179 cases of hypertension,accounting for 43.98%,hand foot syndrome in 264 cases,accounting for 64.86%,bleeding occurs in183 cases,accounting for 44.96%,Proteinuria,hematuria in 146 cases,accounting for 35.87%,diarrhea,abdominal pain in 188 cases,accounting for 46.19%.There were 26 patients with adverse drug reactions,accounting for 4.11%.Most patients can tolerate the adverse reactions.3.Collecting the cases that patients used Apatinib from January 2016 to December 2016 of the hospital.The study was collected the patients’ information included identification,medicines,biochemical data and adverse reactions,to explore the adverse reactions after the listing of the drug.Collected mesylate apatinib 168 cases,which were 10 patients unable to track,without adverse reaction information.In use can be traced for 158 cases of APA mesylate imatinib patients,134 cases of adverse reactions,the adverse reaction rate was 79.76%.Hypertension,hand foot syndrome,hemorrhage,fatigue and weakness for the adverse reactions were more common,56 patients because of intolerance hypertension,gastrointestinal bleeding,listlessness under the guidance of doctors stop or to stop,but there are basically 24 patients without adverse reactions.4.Patients with gastric cancer tend to be younger,male patients are more frequent than female patients,and specific risk factors need to be confirmed on the scale.The chemotherapy regimen of gastric cancer is still based on traditional chemotherapy,but small molecular targeted therapy shows prominent vitality.Targeted therapy is changing the traditional treatment paradigm,and cancer treatment is gradually targeting patients for precise individual medication.Mesylate apatinib high incidence of adverse reactions,but generally tolerated,hypertension,hand foot syndrome,bleeding and fatigue are the common adverse reactions,but the differences between the different patients.